Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/16583
Title: Screening of Aptamers and selective inhibitors for myotonic dystrophy kinase-related CDC42-Binding Kinase (MRCK) by CE-SELEX and Chemical inhibition
Authors: LAI JESYIN
Keywords: aptmaers, MRCK, CE-SELEX
Issue Date: 19-Aug-2009
Source: LAI JESYIN (2009-08-19). Screening of Aptamers and selective inhibitors for myotonic dystrophy kinase-related CDC42-Binding Kinase (MRCK) by CE-SELEX and Chemical inhibition. ScholarBank@NUS Repository.
Abstract: MRCK, a Rac/Cdc42-binding kinase, regulates lamellar actomyosin retrograde flow during membrane protrusion and cell migration. MRCK inhibition therefore affects cell motility. As no known selective MRCK inhibitor is available, screening for MRCK inhibitors is thus required. In this project, aptamers and inhibitors for MRCK were screened. Aptamers, short DNA/RNA sequences which able to bind different targets, can be used as molecular probe for protein detection. Systematic evolution of ligands by exponential enrichment(SELEX) combined with capillary electrophoresis(CE) was used for aptamers selection. MRCK aptamers were selected from and compared between an original method and a modified approach. Concurrently, around 170 chemicals were also screened for MRCK inhibition. Chelerythrine chloride shown to give MRCK inhibition with IC50=0.86 B5M. Weaker inhibition was observed with ROK(IC50=8.5 B5M) and Citron Kinase(IC50=6.5 B5M). Chelerythrine(5 B5M) was able to perturb MRCK in vivo localization. Reduced cell migration was also observed in chelerythrine treatment in wound healing assay.
URI: http://scholarbank.nus.edu.sg/handle/10635/16583
Appears in Collections:Master's Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
LaiJ.pdf3.94 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

292
checked on Dec 11, 2017

Download(s)

204
checked on Dec 11, 2017

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.